- Fee assured
- Awaiting verification
I was appointed as a Consultant Clinical Oncologist in August 2011, specialising in Neuro-Oncology & Acute Oncology/ Cancer of unknown primary.
I qualified in 1995 from Charing Cross & Westminster medical school. In 1999, after completing my general medical training, I commenced my training in Oncology. This was based initially at Charing Cross hospital, and later moving on to the Royal Surrey County hospital in Guildford, and then the Royal Marsden hospital. This training provided me with a broad-ranging experience in the management of cancer. Having worked as a locum consultant for 2 years in London and then Guildford, I then returned to the Royal Marsden hospital to work in the Academic Urology unit where I undertook research in prostate cancer and gained further experience of innovative radiotherapy techniques.
I now specialise in the oncological management of brain and spinal cord tumours, using both chemotherapy and radiotherapy treatments.
I am the lead clinician for the Neuro-oncology Cancer Network multidisciplinary team, and Co-chair of the Sussex Cancer network Neuro-oncology tumour group.
My other specialist area is Acute Oncology, managing all cancer patients admitted with complications of their disease or treatment, and investigating and managing patients admitted to hospital with a new diagnosis of suspected cancer or Cancer of Unknown Primary.
A diagnosis of cancer is a very stressful time for the patient and their relatives – good communication between doctor and patient goes a long way to relieve some of that stress –I strive to achieve that every day.
Areas of interest
Neuro-oncology; Cancer of Unknown Primary
Current NHS consultant posts held
Consultant Clinical Oncologist specialising in Neuro-oncology, Acute Oncology and Cancer of Unknown Primary
Based at Sussex Cancer Centre, Royal Sussex County Hospital, Brighton
and Princess Royal hospital, Haywards Heath
•Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up.
Creak A, Hall E, Horwich A, Eeles R, Khoo V, Huddart R, Parker C, Griffin C, Bidmead M, Warrington J, Dearnaley D. Br J Cancer. 2013 Aug 6;109(3):651-7
•DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. Chudley L, McCann K, Mander A, Tjelle T, Campos-Perez J, Godeseth R, Creak A, Dobbyn J, Johnson B, Bass P, Heath C, Kerr P, Mathiesen I, Dearnaley D, Stevenson F, Ottensmeier C.
Cancer Immunol Immunother. 2012 Nov;61(11):2161-70
•Radiotherapy planning in high grade Gliomas: A survey of current UK practice.
Creak AL, Tree A, Saran F. Clin Oncol (R Coll Radiol). 2011 Apr;23(3):189-98.
•Hypofractionated stereotactic radiotherapy in the management of recurrent or residual medulloblastoma/PNET.
F Saran, B G Baumert, A L Creak, A P Warrington, S Ashley, D Traish, M Brada
Pediatr Blood Cancer. 2007 Oct 16;
•Treatment of recurrent Head and Neck cancer: - Reirradiation or chemotherapy?
A L Creak, K Harrington, C Nutting.
Clin Oncol (R Coll Radiol). 2005 May;17(3):138-47.
- MB BS University of London 1995
- MRCP Royal College of Physicians 1998
- FRCR Royal College of Radiology 2003
Details of entry to specialist register
- Clinical Oncology, 2006
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
Information for healthcare professionals (Bupa patients only, last 12 months)
Clinical supervision and planning for delivery of chemotherapy cycle in the member's home 1-14 days - (1-5)
Clinical supervision and planning for delivery of chemotherapy cycle in the member's home 1-21 days - (1-5)